IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models.
David B. Yaden, Andrea P Berghella, Peter S. Hendricks, Mary E. Yaden, Michael Levine, Julia S Rohde, Sandeep M. Nayak, Matthew W Johnson, Albert Garcia‐romeu
Pharmacological Research 2024 DOI: 10.1016/j.phrs.2023.106998 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Addiction Psilocybin Psychedelic-assisted therapy |
| Keywords | Medication assisted treatment Psychedelics Addiction treatment Substance abuse recovery Mental health innovations Medical research |
| Citations | 12 |
| Key findings | Classic psychedelic-assisted therapies can be integrated into most mainstream evidence-based SUD treatments currently used in clinical settings. |
Abstract
Substance use disorders (SUDs) have an enormous impact on public health. With classic psychedelic-assisted therapies showing initial promise in treating multiple SUDs, it is possible that these treatments will become legally available options for patients with SUDs in the future. This article highlights how classic psychedelic-assisted therapies might be integrated into current clinical practice. We first describe contemporary evidence-based treatments for SUDs and highlight how classic psychedelic-assisted therapies might fit within each treatment. We suggest that classic psychedelic-assisted therapies can be integrated into most mainstream evidence-based SUD treatments that are currently used in clinical settings, indicating broad compatibility of classic psychedelics with contemporary SUD treatment paradigms.
Comparable studies
Other narrative reviews on psilocybin for addiction, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| Psychedelics as anti-inflammatory agents Animal models and cellular studies | 2018 | Review | |
| Psychedelic Drugs in Biomedicine | 2017 | Review | |
| DARK Classics in Chemical Neuroscience: Psilocybin | 2018 | Review | |
| Psilocybin for treating substance use disorders? | 2016 | Narrative review |
Citations in the library
Cited by 12
- The psychedelic (-)-2,5-dimethoxy-4-iodoamphetamine [(-)-DOI] demonstrates efficacy in reducing cocaine reward and motivation in male rats. Psychopharmacology August 1, 2025
- Psychedelic medicine: mechanisms, evidence, and translation to practice BMJ February 23, 2026
- Amid magic and menace: psychiatrists’ attitudes to psilocybin therapy Irish Journal of Psychological Medicine November 7, 2024
- Navigating the “Psychedelic Renaissance”: From Research to Reality International Journal of Mental Health and Addiction April 1, 2024
- Hitting the Reset Button: Ceremonial Use of Peyote and Experiences of Personal Change Journal of Drug Issues August 22, 2024
and 7 more in the library
Cites 44
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
- Long-term follow-up of psilocybin-facilitated smoking cessation The American Journal of Drug and Alcohol Abuse July 21, 2016
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder JAMA Psychiatry August 24, 2022
and 39 more in the library